Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Under Armour Inc Class A — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.79 (market cap $5.08B), while Under Armour Inc Class A trades at $4.8 (market cap $2.03B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 2.5× Under Armour Inc Class A's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Under Armour Inc Class A for 19 Days on average.
| ORKA | UA | |
|---|---|---|
Market Cap | $5.08B | $2.03B |
Volume | 685,276 | 2,242,648 |
Sector | Health | Consumer Cyclical |
52-Week High | $113.08 | $7.88 |
52-Week Low | $26.19 | $3.96 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $4.21B | $3.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Under Armour (UA) trades at $4.81, up 1.05% with bearish technical signals despite recent earnings beats. The company faces significant challenges with negative net income margins (-9.99%) and declining revenues, though it maintains a low P/S ratio of 0.4. Recent Q2 2026 earnings beat expectations but Q1 2026 missed, reflecting ongoing volatility in consumer demand across key markets.
The outlook remains cautious with revenue guidance reductions and negative cash flow trends. Investment opportunity exists in the discounted valuation, but risks include persistent sales declines, competitive pressures, and weak profitability. Analyst sentiment is mixed with 41% buy ratings amid ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
